Trial · NCT01562743
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | Any AEs | 175 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | Treatment-related AEs | 139 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | SAEs | 5 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | Treatment-related SAEs | 1 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | Severe AEs | 3 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | Discontinuation due to AEs | 29 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | Death | 0 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | AEs of special interest 1 | 0 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | AEs of special interest 2 | 0 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | AEs of special interest 3 | 0 | participants | |
| The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters | SPM 962 | Valvular disease of the heart | 0 | participants | |
| Augmentation | SPM 962 | Subjects with augmentation | 11 | participants | |
| Augmentation | SPM 962 | Subjects with clinically significant augmentation | 5 | participants | |
| Change of IRLS Sum Score From the Baseline to Each Visit | SPM 962 | Weeks 8 | -11.4 | Standard Deviation 8.8 | Scores on a scale |
| Change of IRLS Sum Score From the Baseline to Each Visit | SPM 962 | Week 16 | -9.7 | Standard Deviation 9.6 | Scores on a scale |
| Change of IRLS Sum Score From the Baseline to Each Visit | SPM 962 | Week 32 | -9.5 | Standard Deviation 9.1 | Scores on a scale |
| Change of IRLS Sum Score From the Baseline to Each Visit | SPM 962 | Week 44 | -10.4 | Standard Deviation 9.1 | Scores on a scale |
| Efficacy Rate in IRLS Sum Score | SPM 962 | Weeks 8 | 64.1 | 95% Confidence Interval 57.2 to 71.1 | Percentage of participants |
| Efficacy Rate in IRLS Sum Score | SPM 962 | Week 16 | 54.9 | 95% Confidence Interval 47.7 to 62.1 | Percentage of participants |
| Efficacy Rate in IRLS Sum Score | SPM 962 | Week 32 | 57.6 | 95% Confidence Interval 50.5 to 64.7 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01562743/results